CUBT.US Curative Biotechnology Inc
- Market cap
- USD 7.16M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CUBT.US undervalued?
Graham numberThe Graham number of Curative Biotechnology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Curative Biotechnology Inc fundamental analysis
No fundamental analysis for Curative Biotechnology Inc yet.
Curative Biotechnology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhi…
Full company profileCurative Biotechnology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Curative Biotechnology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.1K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Gross Profit | 10.7K | -5.30K | -5.30K | -5.30K | -5.30K | -6.74K | -7.96K | -97.5K | -92.2K | -87.8K | -87.1K |
| Operating Income | -1.52K | -7.10K | -5.45K | -5.45K | -4.64M | -5.01M | -4.47M | -1.93M | -2.44M | -1.50M | -1.33M |
| EBITDA | 3.80K | -1.80K | -8.73K | -150.00 | -4.60M | -5.16M | -4.36M | -2.50M | -2.35M | -1.41M | -1.25M |
| Net Income | -17.4K | -23.0K | -29.9K | 332K | -4.67M | -5.34M | -5.38M | -3.96M | -3.57M | -2.26M | -1.96M |
| EPS | -0.01 | -0.01 | -0.01 | 0.15 | -0.01 | -2.48 | -1.41 | -0.90 | -0.59 | 0.00 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 65.9K | 59.0K | 45.1K | 39.8K | 2.27M | 2.41M | 2.09M | 2.60M | 2.16M | 2.11M | 2.16M |
| Total Liabilities | 702K | 718K | 734K | 397K | 6.80M | 18.8M | 22.6M | 5.75M | 7.08M | 8.20M | 8.55M |
| Shareholders' Equity | -636K | -659K | -689K | -357K | -4.52M | 1.68M | -2.54M | -3.14M | -4.91M | -6.09M | -6.39M |
| Cash & Short-term Investments | - | 0.00 | 0.00 | 0.00 | 161K | 670K | 58.7K | 56.4K | 19.5K | 45.0K | 145K |
| Total Debt | 198K | 199K | 199K | 124.80 | 560K | - | 1.07M | 2.26M | 1.37M | 1.36M | 1.36M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.89K | -150.00 | -150.00 | -150.00 | -190K | -1.60M | -1.54M | -487K | -1.02M | -869K | -1.07M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 6.83K | 34.3K | 21.3K | 76.9K | 14.0K | 1.00 | 4.00 | 0.00 |
| Free Cash Flow | -5.89K | -150.00 | -150.00 | -150.00 | -224K | -1.63M | -1.61M | -501K | -1.02M | -869K | -1.07M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -317.5% | - | - | - | - | - |
| ROA | -26.4% | -39.0% | -66.4% | 834.6% | -205.4% | -221.4% | -257.5% | -152.0% | -164.8% | -107.3% | -90.8% |
| Net Profit Margin | -156.9% | - | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Curative Biotechnology Inc dividends
Curative Biotechnology Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:150 on Mar 23, 2026.
Who owns Curative Biotechnology Inc
- Insiders 0.04%
- Institutions 0.00%
- Public & others 99.96%
- Shares outstanding 8.89M
- Free float 7.47M
Curative Biotechnology Inc company profile
- Company name
- Curative Biotechnology Inc
- Ticker
- CUBT.US
- Exchange
- USA Stocks
- Listed since
- Sep 20, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410
- Phone
- 561 907 8990
- Website
- curativebiotech.com
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
Curative Biotechnology Inc management
4- Mr. Paul M. MichaelsPresident & Executive Chairman · born 1966
- Mr. I. Richard Garr Esq., J.D.CEO, CFO, Principal Accounting Officer & General Counsel · born 1953
- Ms. Pam BisikirskiVice President of Communications
- Dr. Ronald Bordens Ph.D.Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board